Results 31 to 40 of about 16,509 (232)
Cilostazol reduces restenosis after carotid artery stenting [PDF]
, 2010 BACKGROUND: Although carotid artery stenting (CAS) has been proposed as an alternative to carotid endarterectomy in cerebral revascularization, restenosis remains an unsolved issue.
Hayakawa Mikito +6 more
core +1 more source
The effect of antiaggregational therapy on the long-term patency of the femoropopliteal/crural bypass [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2012 Introduction. Antiaggregational therapy can reduce thrombosis development following the arterial reconstruction surgery. In most cases acetylsalicylic acid and ticlopidine are used as antiaggregational agents. Objective.
Vasić Dragan +3 more
doaj +1 more source
Study of Factors to Increase the Usage Rate of Generic Drugs in Platelet Aggregation Inhibitors
Inquiry: The Journal of Health Care Organization, Provision, and Financing, 2023 To reduce pharmacy-related medical expenses, it is necessary to reduce drug costs. One way to achieve this is by increasing the usage rate of generic drugs.
Takaaki Suzuki BS +9 more
doaj +1 more source
Drugs for preventing red blood cell dehydration in people with sickle cell disease. [PDF]
, 2016 BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications.
Ballas, Samir K., Nagalla, Srikanth
core +2 more sources
Ticlopidine-induced cholestatic hepatitis: A case report and review of the literature
Italian Journal of Medicine, 2012 Introduction Cholestatic hepatitis is frequently a drug-related syndrome. We describe the case of a 57-year-old man who developed cholestatic hepatitis two months after starting therapy with ticlopidine following a carotid endarterectomy.Materials and ...
Luigi Anastasio +7 more
doaj +1 more source
BMC Neurology, 2021 Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their relative effectiveness and harms still need to be clarified.
Cinzia Del Giovane +4 more
doaj +1 more source
Newer agents in antiplatelet therapy: a review. [PDF]
, 2012 Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core +3 more sources
Anticoagulant versus antiplatelet therapy for acute ischemic stroke [PDF]
, 2008 Acute ischaemic stroke is a leading cause of death in Canada and should be a priority in health care. This paper defines acute ischaemic stroke and provides current statistics, economic costs, risk factors, treatments, and management options.
core +1 more source
PLoS ONE, 2019 Background and purposeThe ticlopidine/Ginkgo biloba ext. combination drug (Yuclid) is used as an antiplatelet agent for prevention of vascular events since its approval in 2008.
Han-Gil Jeong +3 more
doaj +1 more source
Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
Current Controlled Trials in Cardiovascular Medicine, 2000 The cornerstone in clinical evidence of the relative efficacy of thienopyridines (clopidogrel, ticlopidine) versus aspirin in the secondary prevention of vascular disease is the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events trial ...
Algra Ale, van Gijn Jan
doaj +1 more source